HC Wainwright & Co. analysts reiterated a Buy rating on Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) on February 18, 2026.
Alnylam Pharmaceuticals, Inc. operates in the Healthcare sector. The stock currently trades at $332.68 with a market capitalization of $54.5B.